Akebia Therapeutics (AKBA) shares were down more than 14% in recent Thursday trading after the biopharmaceutical company reported a wider-than-expected Q4 loss.
Earlier, the company reported a Q4 net loss of $0.10 per diluted share. Analysts polled by FactSet expected a loss of $0.08.
Revenue for the quarter ended Dec. 31 was $46.5 million, down from $56.2 million a year earlier. Analysts surveyed by FactSet expected $37.3 million.
The company said it has sufficient funds to run its current operating plan for at least two years.
Price: 1.65, Change: -0.29, Percent Change: -14.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。